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ABSTRACT
Purpose: Previous trials of recombinant human eryth-
ropoietin (rHuEpo) therapy after autologous hematopoietic
stem cell transplantation have administered very high doses
of i.v. rHuEpo starting on day 1 and continuing for 1–2
months until erythroid engraftment and have shown no
benefit of rHuEpo therapy. We sought to establish a more
effective use of rHuEpo in this setting.
Experimental Design: In this report, we show in a first
cohort of 45 lymphoma or myeloma patients undergoing
peripheral blood stem cell transplant (control group) that
endogenous erythropoietin levels are high for the degree of
anemia during the first 3 weeks after transplant but become
adequate or slightly decreased thereafter. We thus enrolled
41 consecutive similar patients in a trial of rHuEpo therapy
at a dose of 500 units/kg/week started on day 30 after the
transplant.
Results: The 12-week probability of achieving hemoglo-
bin (Hb) levels of 13 g/dl was 87% in rHuEpo-treated pa-
tients versus 14% in controls (P  0.0001). Mean Hb levels
were significantly higher in the rHuEpo group than in the
control group from day 42 through day 150 after transplant
(Ps of <0.05 to <0.001). Two of 41 patients in the rHuEpo
group versus 12 of 45 patients in the control group had Hb
levels of <9 g/dl between day 42 and day 100 after the
transplant (P  0.0078).
Conclusions: Anemia after autologous peripheral blood
stem cell transplant is exquisitely sensitive to rHuEpo when
therapy is started soon after engraftment. This is the first
convincing report showing that rHuEpo is effective in this
setting. Our data set the stage for a more rational use of
rHuEpo after autologous hematopoietic stem cell transplan-
tation and should renew interest in erythropoietin therapy
in this setting. Prospective, randomized trials should inves-
tigate the impact of rHuEpo therapy on transfusion require-
ments and quality of life.
INTRODUCTION
Epo2 is the critical regulatory factor of erythropoiesis. In
patients with normal kidney function, serum Epo levels increase
exponentially when an anemia develops. The adequacy of serum
Epo levels is best assessed by the O/P ratio, with a value  1
indicating that Epo production is lower than expected for the
degree of anemia (1). After high-dose chemotherapy, serum Epo
levels first rapidly increase to disproportionately high levels for
1–3 weeks, with peak values usually observed in the first week
after the conditioning regimen (2, 3). With marrow recovery
after an autologous PBSCT, Epo levels progressively return to
an appropriate range, and the duration of this correction phase
inversely correlates with the speed of engraftment (4).
Epo expands erythropoiesis mainly by preventing apo-
ptosis of late erythroid progenitor cells and proerythroblasts (5).
Epo is therefore unlikely to increase red blood production when
endogenous Epo is elevated and nearly all available progenitors
are already surviving and differentiating to mature red cells.
Previous trials of rHuEpo therapy after autologous HSCT have
not taken this pathophysiology of erythropoiesis into account.
All studies have administered very high doses of i.v. rHuEpo
starting on day 1 and continuing for 1–2 months or until eryth-
roid engraftment and have shown no advantage to rHuEpo
therapy (6–15). Therefore, soaking patients with huge doses of
rHuEpo at a time when the erythroid marrow has not developed
enough erythroid precursors to respond and when endogenous
Epo production is appropriate or even excessive for the degree
of anemia may not be the best way to use rHuEpo after trans-
plantation. In the allogeneic setting, we have recently shown
that rHuEpo therapy is very efficient when based on the patho-
physiology of Epo production after allogeneic HSCT, i.e., when
rHuEpo therapy was started 35–1444 days after the transplant
(16). In this study, we demonstrate that Epo production normal-
izes or becomes slightly deficient after day 28 post-autologous
PBSC transplantation and that rHuEpo therapy (500 units/kg/
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week) is very efficient when started around 1 month after the
transplant.
MATERIALS AND METHODS
Patients. Eighty-six recipients of an autologous PBSC
transplant [51 males and 35 females, aged 15–69 years (median
age, 53 years)] were analyzed. They had multiple myeloma (n
46), non-Hodgkin’s lymphoma (n  35), or Hodgkin’s disease
(n  5). Forty-five consecutive patients transplanted in 1994–
1998 in whom serum Epo levels were available served as the
control group, and 41 consecutive patients transplanted after
March 2001 were included in the rHuEpo group (Table 1).
Conditioning before transplantation consisted of various com-
binations of high-dose myeloablative chemotherapy with (n 
18) or without (n  68) total body irradiation. A minimum of
2 106 CD34 PBSCs/kg were infused on day 0. Single-donor
platelet transfusions were given if platelet counts decreased
below 15  109/liter. The trigger for packed RBC transfusions
was 8 g/dl for all patients receiving rHuEpo and 9 g/dl for
patients included in the control group (general change in trans-
fusion policy between the two study periods). Otherwise, the
clinical management of the patients was identical in the two
groups. The control and rHuEpo groups were well balanced for
sex, diagnosis (although there was a tendency for more lym-
phomas among controls and more myeloma in the rHuEpo
group), conditioning, and burst-forming units-erythroid and
CD34 cell doses, but the rHuEpo group was older (P 
0.001). Their pretransplant Hb was identical: 9.9  1.1 g/dl in
the control group versus 10.1  1.7 in the rHuEpo group (P 
0.62). The two groups did not differ for neutrophil and platelet
engraftment or for the numbers of days of G-CSF and platelet
transfusions.
rHuEpo Treatment. Forty-one patients were scheduled
to start rHuEpo on day 30 after PBSCT at a dose of 500
units/kg/week (given s.c.). Initiation of rHuEpo was delayed in
some patients until resolution of ongoing infections. rHuEpo
was administered (three times per week in the 15 first patients
and once weekly in the 26 others) with the aim of achieving and
maintaining Hb levels of 13 g/dl. This initial target was chosen
to ensure easy maintenance of Hb values above 12 g/dl there-
after. Once the target Hb was achieved, the dose of rHuEpo was
reduced by 50% and then further reduced on a biweekly basis so
as to use the lowest dose capable of maintaining the Hb above
12 g/dl but no higher than 14 g/dl. In the rHuEpo group, patients
received i.v. iron (Venofer; 600 mg in three divided doses over
3–6 weeks) when TS was below 20%, unless the target Hb was
already attained. i.v. iron was never given to patients not on
rHuEpo therapy, and functional iron deficiency occurred in only
five cases among them.
Laboratory Analyses. Complete blood counts, percent-
ages of reticulocytes, sTfR (Ref. 17; a quantitative measure of
total erythropoietic activity), and serum Epo levels were meas-
ured as reported previously (16, 18). Based on regression equa-
tions obtained in appropriate reference subjects between Hct on
the one hand and log(Epo) on the other, predicted log(Epo)
values were derived for each Hct, and O/P ratios of O/P Epo
values were calculated (1, 19). The mean  SD Epo O/P ratio
in a cohort of 31 normal donors was 1.03  0.08.
Statistical Methods. Unpaired Student’s t tests were
used to compare biological variables in two groups. Welsh’s
correction was used in case of unequal variance. The number of
transfusions in the same or different groups of patients were
compared using Wilcoxon matched pair or Mann-Whitney U
tests, respectively. Times to response to rHuEpo therapy were
Table 1 Patient characteristics
Control group rHuEpo group P
No. of patients 45 41
Age (mean  SD) (yrs) 43  11 56  8 0.001
Sex (male/female) 29/16 22/19 NS
Disease
Non-Hodgkin’s lymphoma 22 13 NS
Multiple myeloma 19 27
Hodgkin’s disease 4 1
Conditioning regimen
TBIa 11 7 NS
No TBI 34 34
Graft composition (mean  SD)
CD34 cells  106/kg 16.2  29.3 12.5  8.8 NS
BFU-E  104/kg 223  324 177  172 NS
Days to 1% reticulocytes (median) 12 13 NS
Days to unsupported 27% Hct (median) 16 15 NS
Days to last RBC transfusion (median) 10 7 0.05
Days to 0.5  109/liter neutrophils (median) 9 9 NS
Days to 1  109/liter neutrophils (median) 10 10 NS
Days to unsupported 20  109/liter platelets (median) 11 9 NS
Days to unsupported 100  109/liter platelets (median) 17 15 NS
Days to last platelet transfusion (median) 9 7 NS
Number of days of G-CSF (mean  SD) 10 4 11  2 NS
RBC transfusions before day 30 (mean  SD) 3  2 2  2 NS
Platelet transfusions (mean  SD) 3 3 2  2 NS
a TBL, total body irradiation; BFU-E, burst-forming units-erythroid.
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studied by life-table analyses, and Wilcoxon rank tests were
used for comparisons between groups. To allow meaningful
comparison with rHuEpo-treated patients, the time to achieve
Hb levels of 13 g/dl and the time to achieved a 2 g/dl Hb
increment were calculated from day 30 after HSCT also for
patients included in the control group. Areas under the curve
were calculated in each group from day 30 to day 180 using 10.1
g/dl (the mean Hb value on day 30 in the control group) as the
baseline Y value. Because the two groups had a different trigger
value for RBC transfusion, we also calculated the number of
patients in each group who had a Hb value below 9 g/dl at any
time between days 42 and 100 after the transplant. Differences
between groups were calculated by Fisher’s exact test. Statisti-
cal analyses were carried out with Graphpad Prism (Graphpad
Software, San Diego, CA).
RESULTS
Evolution of O/P Epo Ratio in PBSC Recipients Not
Receiving rHuEpo. After PBSCT, serum Epo levels peaked
on day 0 with a mean O/P Epo of 1.19  0.16 (P  0.0001
compared with 31 healthy donors; Fig. 1). Thereafter, endoge-
nous Epo levels decreased slowly and remained adequate for the
degree of anemia until day 21, when levels became inappropri-
ately low. Epo values returned to appropriate levels around day
100 after the transplant. This pattern was superimposable in
multiple myeloma and lymphoma patients.
Erythropoietic Responses to rHuEpo. In the rHuEpo
group, mean O/P Epo was 0.87  0.13 (P  0.0001 compared
with 31 healthy donors), and O/P Epo was below 1.0 in 85% of
the patients when rHuEpo was started. Day 30 serum creatinine
was 11.0  3.9 mg/liter in the control group versus 11.3  5.0
mg/liter (NS) in the rHuEpo group. Before day 30, the evolution
of sTfR, reticulocytes, and Hb was strictly superimposable (Fig.
2), and the speed of erythroid engraftment was similar (Table 1)
in the two groups. Whereas erythropoiesis (as assessed with
sTfR) remained stable between day 30 and day 150 after HSCT
in the control group, it expanded very rapidly above the upper
normal limit for sTfR (7000 g/liter) in the rHuEpo group and
slowly decreased to baseline values when rHuEpo dosage was
reduced (Fig. 2A). This expansion of erythropoietic activity
translated into a progressive Hb response over a period of 10
weeks in the rHuEpo group, whereas Hb levels increased much
more slowly in the control group (Fig. 2B). The 2-week sTfR
increment was highly correlated with the 4-week Hb increment
(r  0.57; P  0.0001; Fig. 3). On the other hand, reticulocyte
counts did not differ between the two groups (Fig. 2C). The
median time to a Hb increment of 2 g/dl was 5 weeks in the
rHuEpo group versus 16 weeks in the control group (P 
0.0001). Hb values of 13 g/dl were achieved after a median of
6 weeks in the rHuEpo group versus 16 weeks in the control
group (P  0.0001; Fig. 4). There were no differences in
response to therapy given weekly or thrice weekly. The median
time to a Hb increment of 2 g/dl and the median time to achieve
Fig. 1 Endogenous serum Epo levels, as assessed by O/P Epo ratios
(mean  SE) after autologous PBSCT. Mean  SE values of 31 normal
donors are also shown (E).
Fig. 2 Evolution of sTfR levels (A), Hb levels (B), and reticulocyte
counts (C) after transplantation. Ps are given for comparisons between
the two groups: , 0.05; , 0.01; , 0.001.
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a Hb level of 13 g/dl were 5 and 9 weeks for patients receiving
rHuEpo thrice weekly and 4 (NS) and 6 (NS) weeks for patients
receiving rHuEpo once weekly. The overall 12- and 15-week
probability of achieving a complete response (Hb  13 g/dl)
was 87% and 100% in the rHuEpo group versus 14% and 22%
(P  0.0001) in the control group. Mean Hb levels were
significantly higher in the rHuEpo group compared with the
control group from day 42 through day 150 after the transplant
(Fig. 2B). The area under the curve of Hb between days 30 and
180 was 279  153 in rHuEpo-treated patients compared with
156  128 in controls (P  0.0001). Platelet counts and neu-
trophils on rHuEpo treatment did not decrease compared with
those of the control group. Day 100 platelet and neutrophil
counts were 131  82  109/liter and 2220  1150  109/liter
in the control group versus 165  81  109/liter and 2610 
990  109/liter in the rHuEpo group, respectively.
Transfusions. Because of the higher Hb trigger for trans-
fusion, the number of RBC transfusions before day 30 was
slightly greater (3 versus 2) in the control group. Eight of 45
patients in the control group versus 0 of 41 patients in the
rHuEpo group required RBC transfusions after day 30 posttrans-
plant (P  0.0059). Four controls with Hb slightly below 9.0
g/dl were not transfused because the patient or physician re-
fused: if they had been transfused, the difference in transfusion
rates between the groups would have been more significant.
However, part of this difference was probably due to the higher
Hb trigger for RBC transfusion in the control group (9 g/dl)
compared with the rHuEpo group (8 g/dl). To circumvent this
limitation, we examined the proportion of patients with a Hb
value  9 g/dl at any time between day 42 and 100 because
these patients would have been transfused at a transfusion
trigger of 9 g/dl. Only 2 of 41 patients in the rHuEpo group
compared with 12 of 45 patients in the control group (P 
0.0078) experienced such a Hb value below 9 g/dl between day
42 and day 100 after the transplant.
Iron Supplementation by i.v. The evolution of TS is
shown in Fig. 5A. TS was increased immediately after the
conditioning regimen and normalized with erythropoietic recov-
ery. After day 30, rHuEpo therapy induced a significant reduc-
tion in TS that later corrected slowly with iron supplementation
and reduced rHuEpo dosage. All but eight patients in the
rHuEpo group experienced functional iron deficiency. Twenty-
one patients received i.v. iron supplementation, and 12 patients
did not because they had already reached the target Hb (n  9),
Fig. 4 Kaplan-Meier plots of time to Hb  13 g/dl.
Fig. 5 A, evolution of TS after the transplant in the rHuEpo group. B,
evolution of Hb and erythropoiesis (assessed by sTfR) in a patient who
developed functional iron deficiency. Whereas response to rHuEpo was
poor until then, erythropoisis and Hb increased rapidly after i.v. iron
administration (arrows).
Fig. 3 Correlation between the 2-week sTfR increment and the 4-week
Hb increment from day 30 after PBSCT. The two extreme patients
showing large sTfR increments but slow Hb responses had cytomega-
lovirus infection and functional iron deficiency, respectively, soon after
initiation of rHuEpo therapy.
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functional iron deficiency was caused by infection (n  2), or
the patient refused (n  1). Fig. 5B illustrates the prompt
response to i.v. iron supplementation in a patient with functional
iron deficiency and poor response to rHuEpo before iron therapy.
DISCUSSION
Elevated serum Epo levels are observed transiently after
intensive conditioning regimens without concomitant changes in
Hb (2, 3, 18). The peak Epo values are usually observed 7 days
after transplantation, at the time of the nadir of erythropoietic
activity. With marrow recovery, Epo levels progressively return
to an appropriate range, and the duration of this correction phase
inversely correlates with the speed of engraftment (4). Thereaf-
ter, endogenous Epo remains appropriate for the degree of
anemia in autologous BMT recipients (2, 3). This study first
shows that after autologous PBSC transplantation, endogenous
Epo levels decreased slowly and remained adequate for the
degree of anemia until day 21, when levels became inappropri-
ately low. Epo values returned to appropriate levels around day
100 after the transplant. These findings suggested that providing
rHuEpo to autologous PBSC recipients around day 30 after the
transplant could be an effective physiological approach.
Previous trials of rHuEpo therapy after autologous HSCT
have not taken this pathophysiology of erythropoiesis into ac-
count. All studies to date have administered very high doses of
i.v. rHuEpo starting on day 1 and continuing for 1–2 months or
until erythroid engraftment and failed to demonstrate efficacy
(6–15). Although only one of them was powered enough to
demonstrate an advantage of rHuEpo therapy (9), the absolute
differences in mean Hb levels or speed of engraftment between
treated and control patients were always minimal. Ayash et al.
(8) administered 1400 units/kg/week rHuEpo for 4 weeks to 10
patients with solid tumors undergoing auto-BMT. Eight of 10
rHuEpo-treated patients versus 20 of 37 historical controls
achieved a Hct of 30% within 32 days (NS), but the number of
RBC transfusions was the same (9 versus 9 units). Locatelli et
al. (10) gave rHuEpo (725 units/kg/week, days 1–30) to 10
children undergoing purged auto-BMT for acute leukemia.
There was no difference with 10 historical controls for reticu-
locyte output, sTfR increase, or the number of transfusions.
Pene et al. (7) gave GM-CSF and rHuEpo (1050 units/kg/week)
to 18 auto-BMT patients until Hb reached 12 g/dl. As compared
with 6 concomitant and 65 historical controls receiving GM-
CSF alone, there was no difference for the median time to a
Hb  12 g/dl or the number of RBC transfusions (10 versus 12
units). Pedrazzini (6) compared seven controls with six patients
receiving rHuEpo (2100 units/kg/week) and GM-CSF from day
10 to the day of neutrophil engraftment and observed no differ-
ence for the median time to a Hb of 10 g/dl or the number of
transfusions before (10 versus 10 units) or after (5 versus 8
units) day 35. Vannucchi et al. (14) gave rHuEpo (1050 units/
kg/week, days 1–21) and G-CSF to 30 patients with lymphoid
malignancies undergoing auto-BMT. Ten patients each received
G-CSF and rHuEpo, G-CSF alone, or no growth factor. Median
time to a Hct of 30% was not faster, and RBC transfusion
needs were not reduced by rHuEpo. Miller and Mills (12)
conducted a randomized trial of rHuEpo (1400 units/kg/week
for 4 weeks followed by 600 units/kg/week for 3 weeks) versus
placebo in 50 patients undergoing auto-BMT with purged mar-
row for acute myelogenous leukemia or non-Hodgkin’s lym-
phoma. The Hb level at day 50 was higher in the rHuEpo group
(10.5 versus 9.5 g/dl; P  0.02), but this did not translate into
reduced RBC requirements (13 versus 15 units). Chao et al. (11)
randomized 35 lymphoma patients to receive rHuEpo (600
units/kg/week, days 1–30) or placebo in addition to G-CSF.
RHuEpo was started 3 weeks before high-dose therapy but was
held during conditioning. There was no difference for the num-
ber of RBC transfusions before day 30 (8 versus 6 units). Link
et al. (9) conducted a prospective, randomized, placebo-
controlled multicenter trial in 114 patients after auto-BMT.
Patients received 1050 units/kg/week rHuEpo until day 41 or
until independence from transfusions with a stable Hb of 9
g/dl. There was no difference in the regeneration of reticulo-
cytes, time to transfusion independence, or the number of RBC
transfusions. Given this negative experience after auto-BMT,
there is only one study after PBSC transplantation. Pierelli et al.
(13) gave rHuEpo (150 units/kg s.c. every 48 hours, days 1–11)
and G-CSF to 15 patients with breast or ovarian carcinoma
undergoing PBSCT. Compared with eight historical controls,
there was no effect on erythroid recovery. The same group
extended their observations with the same protocol, adding 15
patients receiving the same schedule of rHuEpo but with GM-
CSF. There was no impact on RBC transfusion requirements.
Therefore, we took a more physiological approach by pro-
viding rHuEpo to patients 30 days after the transplant. We had
previously shown that a similar attitude was very effective in the
allogeneic HSCT setting (16). The current study proves that this
approach is also very efficient in the autologous PBSCT setting,
with complete correction of Hb achieved in 100% of the patients
(versus 22% in the control group). We elicited to seek a Hb
target of 13 g/dl to demonstrate the full potential of rHuEpo
therapy in the setting of autologous HSCT and to be easily able
to maintain Hb values above 12 g/dl after the target had been
reached. The median time to a Hb increment of 2 g/dl was 5
weeks in the rHuEpo group versus 16 weeks in the control
group. This was obtained with median doses of 500 units/kg/
week, 2–3 times lower than the doses used in previous transplant
trials but similar to doses used in cancer-associated anemia (20).
However, the rate and quality of response were far superior to
those achieved in the anemia of cancer, where the proportion of
patients increasing Hb by 2 g/dl is 40–60%, and it typically
takes 6–16 weeks to increase Hb by 2 g/dl (20). In addition,
there was no difference in response to therapy given weekly or
thrice weekly. This observation confirms the similar results of
rHuEpo therapy given qw or tiw after an allogeneic transplant
when rHuEpo is also started 1 month after the transplant (21).
The expansion of erythropoietic activity by rHuEpo ther-
apy was considerable, reaching sTfR values well above the
normal range in the majority of the patients (Fig. 2). This
expansion reached its maximum even faster than in renal failure
patients (who received lower doses of rHuEpo; Ref. 22). When
rHuEpo therapy was discontinued, erythropoiesis declined
slowly. Hb increases correlated with early signs (sTfR incre-
ment) of expansion of erythropoietic activity. On the other hand,
reticulocyte counts did not differ significantly in controls and
treated patients, underscoring the poor quantitative value of this
parameter in evaluating erythroid response (20, 23, 24). Reticu-
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locytes after day 80 were lower in the rHuEpo group because
therapy was stopped in most patients who then had higher Hb
values compared with untreated patients.
It is now well demonstrated that adequate delivery of iron
to the bone marrow is an important consideration in clinical
settings in which rHuEpo is used (20). Indeed, effective stimu-
lation of erythropoiesis by rHuEpo is often associated with
functional iron deficiency, a situation characterized by an inad-
equate supply of stored iron to provide enough iron for the
increased requirements in the erythroid marrow. This can occur
even in the presence of increased iron stores if these stores
cannot be mobilized fast enough to meet the demand. The
experience in iron-replete renal failure patients treated with
rHuEpo has clearly indicated that oral iron supplementation is
only marginally superior to no iron, whereas i.v. iron substan-
tially improves response to rHuEpo therapy (25). Functional
iron deficiency (as evidenced by low TS or increased percentage
of hypochromic RBCs) has also been observed in a large pro-
portion of cancer patients treated with rHuEpo (26), and many
recent protocols have included a recommendation for i.v. iron
supplementation when there is evidence of functional iron de-
ficiency. In our rHuEpo group, functional iron deficiency oc-
curred frequently, and i.v. iron supplementation generally re-
sulted in prompt erythropoietic response to rHuEpo (Fig. 4).
Whether systematic early i.v. iron supplementation would fur-
ther improve the speed and level of response to rHuEpo remains
to be determined prospectively.
Our study of course has the limitations of nonrandomiza-
tion. The rational use of rHuEpo after autologous HSCT as
proposed here should renew interest in Epo therapy. However,
previous trials that targeted initial erythroid recovery rather than
the more physiologically appropriate period that follows en-
graftment were all negative. Therefore, when we started our
trial, there was no basis for a randomized trial but rather a need
for a large Phase II trial identifying a new approach with an
appropriate dose and timing for rHuEpo therapy after autolo-
gous transplantation. Apart from the multicenter trial conducted
by Link et al. (9), our trial includes by far the largest number of
patients treated with rHuEpo in this setting. The results are
impressive and suggest that autologous HSCT [similar to allo-
geneic HSCT (16)] is associated with the best response rate to
rHuEpo outside the setting of uremia. This trial now justifies the
development of prospective, randomized, placebo-controlled tri-
als that should investigate clinical end points previously shown
to be improved by rHuEpo therapy in other settings, such as
transfusion requirements and quality of life, as well as cost-
effectiveness.
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